PolyPid Secures $4.3M FDA Fee Waiver for D-PLEX₁₀₀ NDA Submission
Event summary
- PolyPid received a $4.3M PDUFA fee waiver from the FDA for its D-PLEX₁₀₀ NDA submission.
- The company plans to initiate rolling NDA submission by the end of March 2026.
- D-PLEX₁₀₀ demonstrated a 60% relative risk reduction in surgical site infections in Phase 3 SHIELD II trial.
- PolyPid is in advanced stages of commercial partnership discussions for the U.S. market.
The big picture
PolyPid's fee waiver and upcoming NDA submission mark a critical step toward bringing D-PLEX₁₀₀ to market, addressing a significant unmet need in surgical site infection prevention. The company's progress reflects broader trends in biopharmaceutical innovation targeting localized drug delivery solutions. With positive Phase 3 trial results and Breakthrough Therapy Designation from the FDA, PolyPid is positioning itself for potential commercial success in a high-value segment of the healthcare market.
What we're watching
- Regulatory Approval
- How the FDA's rolling NDA review process will impact D-PLEX₁₀₀'s approval timeline.
- Commercialization Strategy
- Whether PolyPid can secure a strong commercial partner for U.S. market entry.
- Market Impact
- The pace at which D-PLEX₁₀₀ could capture market share in surgical infection prevention.
Our editorial coverage:
Related topics